RAS inhibitor for advanced solid tumors with RAS mutations
Part of Cancer clinical trials.
This trial tests a new drug that targets cancers with a RAS mutation. It may help people whose cancer has grown after standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer is advanced or has spread and no longer responds to standard treatments.
- Your tumor has a RAS gene mutation (KRAS, NRAS, or HRAS).
- You are able to care for yourself (ECOG score 0 or 1).
- You do not have certain heart, stomach, or brain conditions that could interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new oral medication (AN9025) for people with advanced solid tumors that have a RAS mutation, such as pancreatic, colorectal, lung, or melanoma. It aims to see if the drug can shrink tumors or slow their growth when other treatments have stopped working.
This Phase 1 trial tests ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. It may help people whose standard targeted treatments are no longer working, or who cannot receive standard approved therapies.
This trial is testing a new drug called BG-85738, which may target cancer cells that have a specific change (mutation) in the RAS gene. The goal is to see if it is safe and works against advanced or spreading solid tumors.
This trial is testing an experimental drug for people whose cancer has spread and has a specific gene change called RAS. The study aims to see if the drug is safe and helps shrink tumors.
This trial tests a new oral drug called RNK08954 for people with advanced solid tumors that have a specific KRAS G12D genetic change. The drug targets this mutation to try to stop tumor growth. It is for patients who have already had other treatments and may not have many options left.
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.